Table 3.
Group | TC | HDL-C | TC/HDL-C | Non HDL-C | LDL-C | TG |
---|---|---|---|---|---|---|
NC | 84.38a ± 1.74 | 46.75a ± 1.82 | 1.83a ± 0.1 | 37.63a ± 2.83 | 19.8 a ± 2.9 | 89.0a ± 2.10 |
MC | 307.50b ± 11.40 | 39.40b ± 1.27 | 7.84b ± 0.3 | 268.1b ± 10.9 | 236.4 b ± 9.9 | 158.5b ± 6.50 |
A | 197.80c ± 6.14 | 43.25a ± 1.31 | 4.58c ± 0.2 | 154.1c ± 5.7 | 131.9 c ± 5.8 | 110.7c ± 4.60 |
N1 | 259.80d ± 6.00 | 38.40b ± 1.29 | 6.84d ± 0.3 | 221.4d ± 6.6 | 197.4 d ± 5.8 | 120.1d ± 5.04 |
NN1 | 267.50d ± 6.53 | 40.50b ± 1.05 | 6.63d ± 0.2 | 227d ± 6.5 | 201.8 d ± 6.5 | 125.6d ± 2.50 |
N2 | 277.50e ± 5.05 | 40.40b ± 1.28 | 6.93d ± 0.3 | 237.1d ± 5.4 | 210.5 d ± 5.4 | 133.2df ± 1.98 |
NN2 | 275.30d ± 6.20 | 40.60b ± 0.5 | 6.8d ± 0.2 | 234.6d ± 6.4 | 207.1d ± 6.2 | 137.4f ± 2.00 |
AN1 | 122.00f ± 2.58 | 47.25a ± 1.63 | 2.61e ± 0.1 | 74.75e ± 2.99 | 53.9e ± 3.4 | 104.1ce ± 3.50 |
ANN1 | 123.60f ± 2.80 | 45.25a ± 0.77 | 2.7eg ± 0.1 | 78.38e ± 3.54 | 58.6 e ± 3.7 | 98.75ae ± 3.04 |
AN2 | 148.50g ± 3.60 | 46.75a ± 1.39 | 3.2fg ± 0.1 | 101.8f ± 3.4 | 80.3f ± 3.8 | 107.2ce ± 4.30 |
ANN2 | 155.60g ± 3.10 | 46.00a ± 1.16 | 3.4f ± 0.1 | 109.6f ± 3.6 | 87.7f ± 3.1 | 109.8ce ± 3.80 |
Values are expressed as means ± SE (n = 8). Significance was considered at p < 0.05 within columns where different letters indicate statistical significance.
.NC control normal, MC metabolic syndrome control, A rats given atorvastatin drug, N1 rats received nutraceutical 1, NN1 rats treated with nutraceutical 1nanostructure, N2 rats received nutraceutical 2, NN2 rats given nutraceutical 2 nanostructure, AN1 rats taken atorvastatin drug with nutraceutical 1, ANN1 rats given atorvastatin drug with nutraceutical 1 nanostructure, AN2 rats treated with atorvastatin drug with nutraceutical 2, ANN2 rats received atorvastatin drug with nutraceutical 2 nanostructure, TC total cholesterol, TG triglycerides, HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol.